An EGFR/HER2-Bispecific and Enediyne-Energized Fusion Protein Shows High Efficacy against Esophageal Cancer

Esophageal cancer is one of the most common cancers, and the 5-year survival rate is less than 10% due to lack of effective therapeutic agents. This study was to evaluate antitumor activity of Ec-LDP-Hr-AE, a recently developed bispecific enediyne-energized fusion protein targeting both epidermal gr...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Xiao-Fang, Zhu, Xiao-Fei, Yang, Wan-Cai, Zhang, Sheng-Hua, Zhen, Yong-Su
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963964/
https://www.ncbi.nlm.nih.gov/pubmed/24664246
http://dx.doi.org/10.1371/journal.pone.0092986

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963964/
https://www.ncbi.nlm.nih.gov/pubmed/24664246
http://dx.doi.org/10.1371/journal.pone.0092986

Ejemplares similares